🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Long-term outcomes and OS for zanidatamab + CTx in HER2+ mGEA: 4-year follow-up #ASCO25 🔎Phs-2 👉ORR 76 %m DoR 18.7 mo 👉mPFS 12.5 mo 👉mOS 36 mo 👉Manageable safety 👉95% concordance btw ctDNA & IHC 🧐 strong efficacy signal, phase-3 data awaited ESMO - Eur. Oncology

💙 Gracias, Rentmultimedia ‼️ Vuestra donación se destinará al proyecto #ImmunoCLAUD para avanzar en la investigación del cáncer gástrico y poder desarrollar, en un futuro, nuevas opciones terapéuticas para los pacientes. 👉 linke.to/ImmunoCLAUDVHIO

¡Gracias por la oportunidad! 💜 #ImmunoCLAUD, una herramienta desarrollada en Vall d’Hebron Institute of Oncology (VHIO) para optimizar la selección de tratamiento en pacientes con tumores gastroesofágicos. Seguimos avanzando🎗️Teresa Macarulla TIAN TIAN Daniel Acosta Eyzaguirre

🧬 En #PromesasVsSaurios, MESA 9: cáncer digestivo no colorrectal ▶️ Hepatocarcinoma ▶️ TNEs y radionúclidos ▶️ ADC gástrico local/avanzado Con Mariona @JHernando_Onco Eduardo Terán Ana Fernández Montes, MD,Phd 🎟️ Inscríbete, última oportunidad: oncopromesas-oncosaurios.com

Últimos avances en #UpperGI 💥 #OncopromesasVsOncosaurios Gracias por la invitación! No te lo pierdas y apúntate 🙇🏽👇🏼

Pleased to report FGFR2b expression in gastric cancer and relationship with other biomarkers ESMO Open ESMO - Eur. Oncology. The results of bemarituzumab phase 3 studies are awaited.OncoAlert OncoDaily sciencedirect.com/science/articl…

🎯 Top Sessions to Watch at #ESMOGI25 🔥 From practice-changing data to paradigm debates 👇 🔵 Late Breakers: 1️⃣ MATTERHORN (LBA4) – Durva+FLOT: EFS & PROs in G/GEJ 2️⃣ PANOVA-3 (LBA3) – TTFields: QoL & pain in LAPC 3️⃣ TALENTACE (LBA2) – Atezo/Bev+TACE in HCC: Phase 3 results 🚀

Very proud 😊😊 of all the #Spanish faculty and fellow representation at #MCCR25 Fundación Jiménez Díaz Vall d’Hebron Institute of Oncology (VHIO) Hospital 12 Octubre The START Center and others… 🫶 SEOM

Truly grateful for this unique opportunity 🤩 Looking at the future of oncology with an incredible group #PDG10 🔭 Thank you for the mentoring! #MCCR25 AACR ESMO - Eur. Oncology EORTC

Gran repaso de las novedades en #UpperGI 🙇🏽 #PromesasVsSaurios Gracias por la invitación!

📍#TTDCOLOQUIO 'Algoritmo de manejo terapéutico en cáncer EG tras las novedades presentadas en ASCO y ESMO - Eur. Oncology GI 2025' 📅4-JUL ⏰16h Coordina: Dra. María Alsina 📢Dras. Virginia Arrazubi; Cinta Hierro. ✍️ttdgroup.org/contenidos/for… MSD España Jazz Pharmaceuticals ✅Abierto a especialistas

Great news for GEA💥 Positive Phase 3 topline results for bemarituzumab in FGFR2b+ first-line GEA 🤩 Molecular subtyping in gastric cancer is now a REALITY in our clinical practice⁉️ ⁦Grupo Español de Tratamiento de Tumores Digestivos⁩ ⁦ACTEG⁩ amgen.com/newsroom/press…

💥#ESMOGI25 Phase I/II: Givastomig (CLDN18.2/4-1BB) + nivo + mFOLFOX in mGEC 🎯 ORR 71% overall (83% @ 8–12 mg/kg!) ▪️ Active in both PD-L1 ≥5 & CLDN18.2 ≥75% A bispecific shot that might just hit two targets at once 🎯🔁 OncoAlert ESMO - Eur. Oncology SEOM Grupo Español de Tratamiento de Tumores Digestivos

Such a promising combo in mGEA 💥 Worth noting🕵🏼‍♂️: CLDN18.2 cutoff at 1%, independent of PD-L1 expression. Synergistic effect clearly demonstrated — eager to see results from upcoming trials… ESMO - Eur. Oncology #ESMOGI25 Grupo Español de Tratamiento de Tumores Digestivos

🔥Burning questions still unanswered in chemo-immunotherapy for gastroesophageal cancer, by Dr. Florian Lordick #ESMOGI25 ESMO - Eur. Oncology

Brilliant review on the use of targeted therapies in gastroesophageal adenocarcinoma 🙇🏼🤩 FGFR2b enters the field 🏏 Eagerly awaiting FORTITUDE-101 & 102 results 🤯 More options for our patients⁉️ Lizzy Smyth ESMO - Eur. Oncology Grupo Español de Tratamiento de Tumores Digestivos #ESMOGI25

Thrilled to share at #ESMOGI25 ESMO - Eur. Oncology Claudin 18.2 expression overlap landscape and its association with IO outcomes in GEA‼️A hot topic with many open questions 🔍 Stay tuned for more at #ESMO25, where we’ll present insights from a Spanish-Italian cohort 🙇🏼📝 Vall d’Hebron Institute of Oncology (VHIO)

Hands up—huge congratulations on such outstanding work! 👏🏼

The Top Most Active Cancer Institutes that were leading the conversation during ESMO - Eur. Oncology Gastrointestinal (GI) Cancers Annual Congress 2025, ranked based on oncologists' reactions and engagement on X. Explore more #ESMOGI25 insights and data: t.ly/kXH8X #LARVOL

No te pierdas lo más destacado de #ESMOGI25 de la mano de Oncobites.tv 👇🏽